Your SlideShare is downloading. ×

ANGLE plc aims to signs more deals

56
views

Published on

Andrew Newland, chief executive of Angle plc (LON:AGL), tells Proactiveinvestors that the company is now expanding the market it is targeting for Parsortix, its blood separation technology. Andrew …

Andrew Newland, chief executive of Angle plc (LON:AGL), tells Proactiveinvestors that the company is now expanding the market it is targeting for Parsortix, its blood separation technology. Andrew also says that Angle is 'close' to achieving US Food & Drug Administration (FDA) approval.

Published in: Investor Relations

0 Comments
1 Like
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total Views
56
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
0
Comments
0
Likes
1
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide